121 related articles for article (PubMed ID: 35123616)
1. [Correlation and Influencing Factors of SUVmax and Ki-67 in Non-Hodgkin Lymphoma].
Li J; Zhao M; Yuan L; Liu Y; Ma N
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):136-140. PubMed ID: 35123616
[TBL] [Abstract][Full Text] [Related]
2. Correlations between maximum standardized uptake value measured via
Li H; Wang X; Zhang L; Yi X; Qiao Y; Jin Q
J Cancer Res Ther; 2019; 15(7):1581-1588. PubMed ID: 31939441
[TBL] [Abstract][Full Text] [Related]
3. [Metabolic activity measured by ¹⁸F-FDG PET/CT in newly diagnosed patients with non-Hodgkin lymphoma: correlation with immunophenotype].
Zhang J; Wang R; Fan Y; Fu Z; Zhang X; Liao X; Liu M; Kang L; Cui Y; Wang Y; Jiang Q
Zhonghua Yi Xue Za Zhi; 2014 Sep; 94(33):2576-9. PubMed ID: 25511487
[TBL] [Abstract][Full Text] [Related]
4. Value of
Alobthani G; Romanov V; Isohashi K; Matsunaga K; Watabe T; Kato H; Tatsumi M; Shimosegawa E; Hatazawa J
Hell J Nucl Med; 2018; 21(1):7-14. PubMed ID: 29550841
[TBL] [Abstract][Full Text] [Related]
5. Standardized uptake value for (18)F-fluorodeoxyglucose is correlated with a high International Prognostic Index and the presence of extranodal involvement in patients with diffuse large B-cell lymphoma.
Akkas BE; Vural GU
Rev Esp Med Nucl Imagen Mol; 2014; 33(3):148-52. PubMed ID: 24094371
[TBL] [Abstract][Full Text] [Related]
6. SUVmax in FDG-PET at the biopsy site correlates with the proliferation potential of tumor cells in non-Hodgkin lymphoma.
Watanabe R; Tomita N; Takeuchi K; Sakata S; Tateishi U; Tanaka M; Fujita H; Inayama Y; Ishigatsubo Y
Leuk Lymphoma; 2010 Feb; 51(2):279-83. PubMed ID: 20038236
[TBL] [Abstract][Full Text] [Related]
7. Comparison of clinical and PET-derived prognostic factors in patients with non-Hodgkin lymphoma: a special emphasis on bone marrow involvement.
Kupik O; Akin S; Tuncel M; Eren G; Türker A; Kars A; Erbaş B
Nucl Med Commun; 2020 Jun; 41(6):540-549. PubMed ID: 32209829
[TBL] [Abstract][Full Text] [Related]
8. Correlation of 18F-FDG PET/CT SUVmax with clinical features, D-dimer and LDH in patients with primary intestinal lymphoma.
Zhou S; Chen W; Lin M; Chen G; Chen C; Huo C; Du X
J Int Med Res; 2021 Jul; 49(7):3000605211029809. PubMed ID: 34250823
[TBL] [Abstract][Full Text] [Related]
9. [Pretreatment evaluation of
Peng P; Wu N; Tao XL; Liu Y; Lyu L; Cheng X
Zhonghua Zhong Liu Za Zhi; 2022 Apr; 44(4):370-376. PubMed ID: 35448927
[No Abstract] [Full Text] [Related]
10. Utility of FDG-PET in predicting the histology of relapsed or refractory lymphoma.
Wai SH; Lee ST; Cliff ERS; Bei M; Lee J; Hawkes EA; Chong G
Blood Adv; 2024 Feb; 8(3):736-745. PubMed ID: 38127277
[TBL] [Abstract][Full Text] [Related]
11. Whole-body diffusion-weighted MRI and (18)F-FDG PET/CT can discriminate between different lymphoma subtypes.
Mosavi F; Wassberg C; Selling J; Molin D; Ahlström H
Clin Radiol; 2015 Nov; 70(11):1229-36. PubMed ID: 26208992
[TBL] [Abstract][Full Text] [Related]
12. [The value of (18)F-FDG PET-CT imaging in predicting the malignant potential of GIST].
Li SX; Tang MD; Lin DY; Liu DJ; Lyu QH; Zhang JP; Cai ZH
Zhonghua Zhong Liu Za Zhi; 2017 Nov; 39(11):821-827. PubMed ID: 29151288
[No Abstract] [Full Text] [Related]
13. SUV on dual-phase FDG PET/CT correlates with the Ki-67 proliferation index in patients with newly diagnosed non-Hodgkin lymphoma.
Chang CC; Cho SF; Chen YW; Tu HP; Lin CY; Chang CS
Clin Nucl Med; 2012 Aug; 37(8):e189-95. PubMed ID: 22785526
[TBL] [Abstract][Full Text] [Related]
14. Different roles of surveillance positron emission tomography according to the histologic subtype of non-Hodgkin's lymphoma.
Kim YR; Kim SJ; Cheong JW; Kim Y; Jang JE; Cho H; Chung H; Min YH; Yang WI; Cho A; Kim JS
Korean J Intern Med; 2021 Mar; 36(Suppl 1):S245-S252. PubMed ID: 32550718
[TBL] [Abstract][Full Text] [Related]
15. [Correlation of ¹⁸F-FDG uptake with tumor-proliferating antigen Ki-67 expression in aggressive lymphoma].
Liang Y; Wu N; Fang Y; Huang WT; Zhang H; Zheng R; Zhang WJ; Liu Y; Li XM
Zhonghua Zhong Liu Za Zhi; 2013 May; 35(5):356-60. PubMed ID: 24054012
[TBL] [Abstract][Full Text] [Related]
16. Nomograms based on SUVmax of
Li H; Shao G; Zhang Y; Chen X; Du C; Wang K; Gao Z
Cancer Imaging; 2021 Jan; 21(1):9. PubMed ID: 33419476
[TBL] [Abstract][Full Text] [Related]
17. 18F-FDG PET/CT in gastric MALT lymphoma: a bicentric experience.
Albano D; Bertoli M; Ferro P; Fallanca F; Gianolli L; Picchio M; Giubbini R; Bertagna F
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):589-597. PubMed ID: 27619357
[TBL] [Abstract][Full Text] [Related]
18. Correlation of 18F-fluorodeoxyglucose uptake on positron emission tomography with Ki-67 index and pathological invasive area in lung adenocarcinomas 30 mm or less in size.
Murakami S; Saito H; Sakuma Y; Mizutani Y; Ishikawa Y; Kondou T; Oshita F; Yokose T; Kameda Y; Suga Y; Ito H; Tsuboi M; Nakayama H; Noda K; Yamada K
Eur J Radiol; 2010 Aug; 75(2):e62-6. PubMed ID: 20005653
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of SUVmax measured by pretreatment 18F-FDG PET/CT in patients with primary gastric lymphoma.
Hwang JP; Lim I; Byun BH; Kim BI; Choi CW; Lim SM
Nucl Med Commun; 2016 Dec; 37(12):1267-1272. PubMed ID: 27482643
[TBL] [Abstract][Full Text] [Related]
20. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
